News & Updates


Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

October 27, 2018 10:09 ET | Source:  Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »


Pravin U. Dugel, MD At EURETINA 2018: Brolucizumab For Neovascular Age-Related Macular Degeneration

   At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the… Read More »


Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

Lausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings… Read More »


Dr. Pravin Dugel: Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease

PALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed.  First patient in was dosed on July 12, 2018 and last patient… Read More »



Dr. Derek Kunimoto Discusses the CentraSight Implantable Telescope – AZTV Phoenix

Dr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central… Read More »



Healthy Vision Awareness!

According to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support… Read More »